The latest update is out from Genedrive ( (GB:GDR) ).
Genedrive plc has been awarded additional funding under the DEVOTE programme, a collaboration aimed at integrating genomic technology into clinical practice. The company received approximately £1.2 million in funding to support the validation and UKCA certification of its Genedrive® CYP2C19 ID Kit, which has been recommended by NICE for use in the NHS. The success of the DEVOTE programme has led to further funding of £0.2 million to enhance user experiences in rapid genetic testing environments, strengthening Genedrive’s position in the market and reducing development costs.
More about Genedrive
Genedrive plc is a UK-based pharmacogenetic testing company specializing in the development and commercialization of rapid, low-cost, and easy-to-use point-of-care pharmacogenetic platforms. These platforms are designed to assist clinicians in making informed decisions about medication choices and dosages based on genetic information, particularly in emergency healthcare settings. The company’s flagship products, the Genedrive® MT-RNR1 ID Kit and the Genedrive® CYP2C19 ID Kit, are used in NHS settings and have been recommended by NICE for their effectiveness in improving patient outcomes.
YTD Price Performance: -37.96%
Average Trading Volume: 3,212,922
Technical Sentiment Signal: Strong Buy
Current Market Cap: £8.31M
See more insights into GDR stock on TipRanks’ Stock Analysis page.